Inventiva accelerated boardroom change and signaled continuity as it targets a Phase III readout for lanifibranor in MASH. The French biotech named new executives across finance, legal, and people operations, including Axel-Sven Malkomes as CFO, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer. The updates come as Inventiva looks ahead to a Phase III readout in 4Q26 for lanifibranor in metabolic dysfunction-associated steatohepatitis. With leadership roles shifting while the Phase III milestone approaches, investors will likely watch whether governance and operational execution stay aligned with the timing of the company’s regulatory path. Executives’ prior experience spans publicly traded biotech and major life-science organizations, with Coles previously at Vivet Therapeutics and Herbster at Sage Therapeutics. Inventiva’s governance reshuffle underscores how near-term late-stage catalysts continue to shape C-suite priorities.